Dupixent Denied for Eosinophilic Esophagitis (EoE)? How to Appeal

Dupixent (dupilumab) became the first FDA-approved biologic treatment for eosinophilic esophagitis (EoE) in 2022 — a significant milestone for patients with this chronic, often debilitating inflammatory disease. Despite this approval, many patients face insurance denials for Dupixent for EoE, leaving them unable to access this targeted therapy. Here's everything you need to know to appeal successfully.

What EoE Is and Why Dupixent Is Needed

Eosinophilic esophagitis is a chronic, allergic inflammatory condition in which the immune system triggers an abnormal eosinophil-driven response in the esophagus. Symptoms include difficulty swallowing (dysphagia), food impaction, chest pain, and in children, feeding difficulties and failure to thrive.

EoE is driven by IL-4 and IL-13 signaling — the same inflammatory pathway that Dupixent targets. By blocking these cytokines, dupilumab reduces esophageal eosinophilia and significantly improves symptoms and endoscopic findings.

In the LIBERTY-EoE TREET clinical trial, Dupixent at 300mg weekly demonstrated:

• 59% of patients achieving histologic remission (eosinophil count ≤6 per high-power field)
• Significant improvement in dysphagia symptom scores
• Improved endoscopic findings compared to placebo

For patients who have not achieved adequate symptom control with dietary elimination, proton pump inhibitors (PPIs), or topical swallowed corticosteroids, Dupixent represents the first targeted pharmacological option approved specifically for EoE.

Common Denial Reasons for Dupixent for EoE

Step therapy requirements: Insurers typically require documented failure of dietary elimination therapy, PPIs, and topical/swallowed corticosteroids (typically budesonide oral suspension or fluticasone) before approving Dupixent.

"Experimental" or "investigational" classification: Some plans have not yet updated their formularies or medical policies to reflect the May 2022 FDA approval of Dupixent for EoE, incorrectly classifying it as unproven.

Lack of specialist documentation: EoE diagnosis must be confirmed by biopsy (≥15 eosinophils per high-power field) and the appeal should include gastroenterology or allergy specialist involvement.

Formulary exclusion: As a newer indication for Dupixent, some plan formularies haven't yet added it under the EoE indication specifically.

Age restriction issues: Dupixent is approved for EoE in adults and pediatric patients 1 year and older, but older plan criteria may not reflect the pediatric indication expansion.

Step-by-Step: How to Appeal a Dupixent EoE Denial

Step 1: Get the written denial and identify the exact reason. Is it step therapy, experimental classification, or formulary? Each requires a targeted response.

Step 2: Confirm your biopsy-confirmed EoE diagnosis documentation. Endoscopy reports showing ≥15 eosinophils/HPF and the associated pathology report must be part of your appeal.

Step 3: Document all prior EoE treatments. List dietary elimination trials (elemental formula, 6-food elimination diet), PPI duration and doses tried, and any topical corticosteroids used — including how long they were used and how symptoms responded.

Step 4: Have your gastroenterologist or allergist write a detailed Letter of Medical Necessity. The LMN should include biopsy results, symptom severity, prior treatment history, functional impairment (dysphagia, food impaction history), and clinical rationale for Dupixent.

Step 5: Challenge any "experimental" classification directly. Include the FDA approval announcement (May 20, 2022) and the LIBERTY-EoE TREET trial citations. Dupixent has full regulatory approval for EoE — calling it experimental is factually incorrect.

Step 6: File your internal appeal with all documentation and request peer-to-peer review.

Step 7: File an external appeal if needed. External Independent Review: Complete Guide" class="auto-link">External reviewers who see FDA approval documentation and biopsy-confirmed disease regularly overturn these denials.

What to Include in Your EoE Appeal Letter

• Policy/member information and claim reference
• Biopsy report confirming EoE diagnosis (eosinophil count per HPF)
• Endoscopy report including EREFS (Endoscopic Reference Score) findings
• Symptom documentation: dysphagia severity, food impaction history, weight loss, nutritional impact
• Prior treatment history: PPI names/doses/duration, topical corticosteroids, dietary trials
• Letter of Medical Necessity from gastroenterologist or allergist
• FDA approval for Dupixent in EoE (May 2022)
• LIBERTY-EoE TREET trial citation
• AGA (American Gastroenterological Association) EoE guideline citations
• Response to any "experimental" claim with regulatory approval documentation

Success Tips for EoE Dupixent Appeals

Lead with FDA approval. If the plan calls Dupixent experimental for EoE, this is simply factually wrong. The FDA approved it for this precise indication in May 2022 after Phase 3 trial evidence. Document this clearly, and note that denying FDA-approved medications as experimental is contrary to established insurance practice.

Include the biopsy. EoE is a histologically diagnosed condition — eosinophil counts from biopsies are essential for establishing that this is a genuine, confirmed diagnosis rather than a functional disorder.

Quantify functional impairment. Food impaction requiring emergency endoscopic removal is a serious medical event. If you've had food impaction episodes, these are compelling evidence that the disease is severe and inadequately controlled.

Highlight the unique approval. Point out that Dupixent is the only FDA-approved biologic specifically for EoE — there are no approved alternatives in this class. Step therapy to unproven agents for EoE is inappropriate when Dupixent is the only approved option.

Fight Back With ClaimBack

EoE is a real, biopsy-confirmed disease that deserves the only FDA-approved biologic treatment. If your insurer denied Dupixent for your EoE diagnosis, ClaimBack can help you build a fact-based, compelling appeal.

Start your EoE appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied